News
-
-
-
PRESS RELEASE
Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Jaguar Health, Inc. announces extension of FDA approval for Canalevia®-CA1 for chemotherapy-induced diarrhea in dogs, seeks partner for NP300 development at Pet Connect conference -
-
-
-
-
-
-